AP-472

· Appello Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AP-472, covering 2026-04-06 to 2026-04-06. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations [Phase 2]

See pricing